HUMA vs AORT vs NVCR vs ATRC

For growth investors, AtriCure, Inc.

(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Artivion, Inc. (AORT) offers the better valuation at 168. 5x trailing P/E (98. 7x forward), making it the more compelling value choice. Analysts rate Humacyte, Inc. (HUMA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Artivion, Inc.

is actually cheaper at 98. 7x.

Over the past 5 years, Artivion, Inc.

(AORT) delivered a total return of +15. 4%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: AORT returned +188. 9% versus HUMA's -88. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Artivion, Inc.

(AORT) is the lower-risk stock at 0. 63β versus Humacyte, Inc. 's 3. 27β — meaning HUMA is approximately 420% more volatile than AORT relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AtriCure, Inc.

(ATRC) is pulling ahead at 14. 9% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Artivion, Inc. grew EPS 165. 6% year-over-year, compared to -17. 8% for Humacyte, Inc.. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Artivion, Inc.

(AORT) is the more profitable company, earning 2. 2% net margin versus -420. 2% for Humacyte, Inc. — meaning it keeps 2. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AORT leads at 6. 1% versus -1197. 7% for HUMA. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Artivion, Inc.

(AORT) trades at 98. 7x forward P/E versus 370. 7x for AtriCure, Inc. — 272. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HUMA: 177. 8% to $3. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Artivion, Inc.

(AORT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +188. 9% 10Y return). Humacyte, Inc. (HUMA) carries a higher beta of 3. 27 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AORT: +188. 9%, HUMA: -88. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.